HemoGenyx Pharmaceuticals Plc (GB:HEMO) has released an update.
HemoGenyx Pharmaceuticals to Present Innovative Immunotherapy at CBD S&T Conference: HemoGenyx Pharmaceuticals, a clinical-stage biopharmaceutical company, has announced its upcoming presentation at the 2024 Chemical and Biological Defense Science & Technology Conference. The company will showcase its proprietary Chimeric Bait Receptor (CBR) platform, an advanced immunotherapy aimed at reprogramming immune cells to combat viral infections and cancer. The participation is expected to enhance HemoGenyx’s biodefense profile and foster collaborations and investment opportunities.
For further insights into GB:HEMO stock, check out TipRanks’ Stock Analysis page.
